{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:49:04Z","timestamp":1783050544930,"version":"3.54.6"},"reference-count":36,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Dry powder inhalers (DPIs) are passive devices, which rely on a patient\u2019s inspiratory effort for drug dispersion and delivery. The aim of this study was to assess how acute bronchoconstriction affects the ability to use Easyhaler DPI in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study was conducted as part of a parallel-group clinical trial assessing use of Salbutamol Easyhaler, Budesonide-formoterol Easyhaler and salbutamol pMDI with spacer during a methacholine challenge (MC) test. The inhalations through both Easyhaler variants, the inhaler for the single active substance product (EH-mono) and the inhaler for the combination product (EH-combi), were recorded at baseline and during bronchoconstriction. Peak inspiratory flow (PIF), flow rate acceleration and inhalation volume after PIF were compared to the criteria for successful inhalation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The study population consisted of 120 adult subjects indicated for MC as a diagnostic test for asthma, with 60 subjects in both Easyhaler arms. With EH-combi 98.3% and 91.4% passed the criteria (PIF \u226530 L\/min, inhalation acceleration \u22650.7 L\/s\n                      <jats:sup>2<\/jats:sup>\n                      , and inhalation volume \u2265500 mL after PIF) for successful inhalation at baseline and during bronchoconstriction, respectively. With EH-mono, success rates were 95.0% and 88.1% at baseline and during bronchoconstriction, respectively. The most common reason for not passing the criteria was slow inhalation acceleration. Aside from two subjects using EH-mono during bronchoconstriction, all subjects were able to generate PIF \u2265 30 L\/min.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>During an acute obstructive event, the vast majority of patients have no difficulty in achieving sufficient PIF, inhalation acceleration, and volume after PIF when using an Easyhaler DPI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jamp.2024.0045","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T03:22:42Z","timestamp":1738898562000},"page":"83-89","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Inspiratory Profiles Through Easyhaler Dry Powder Inhaler During Acute Bronchoconstriction"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9833-6965","authenticated-orcid":false,"given":"Ville A.","family":"Vartiainen","sequence":"first","affiliation":[{"name":"Heart and Lung Center, Helsinki University Hospital, Finland and Faculty of Medicine, University of Helsinki, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Tikkakoski","sequence":"additional","affiliation":[{"name":"Clinical physiology and nuclear medicine, Tampere University Hospital, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Pekka","family":"Malmberg","sequence":"additional","affiliation":[{"name":"Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liisa","family":"Vuotari","sequence":"additional","affiliation":[{"name":"Clinical physiology and nuclear medicine, Tampere University Hospital, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"L\u00e4helm\u00e4","sequence":"additional","affiliation":[{"name":"Orion Corporation, Espoo, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Sairanen","sequence":"additional","affiliation":[{"name":"Orion Corporation, Espoo, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Vahteristo","sequence":"additional","affiliation":[{"name":"Orion Corporation, Espoo, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussi","family":"Karjalainen","sequence":"additional","affiliation":[{"name":"Allergy Centre, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri","family":"Lehtim\u00e4ki","sequence":"additional","affiliation":[{"name":"Allergy Centre, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00166410"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2017.1376"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.07.013"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2019.1556"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/08942680252908593"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/089426803764928329"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2023.2179984"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.026"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.04.010"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2000.0788"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(03)00139-2"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2005.04.009"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00027405"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/1865-1380-5-16"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01574.x"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13847"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000083687"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901963"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2010.0862"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02185.x"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2007.07.006"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-20-2112"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S298514"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107693"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01526-2016"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1590ST"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S11474"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200020010-00004"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-016-0025-z"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2013.1099"},{"key":"e_1_3_4_32_2","unstructured":"CHMP. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. 2009. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-requirements-clinical-documentation-orally-inhaled-products-including-requirements-demonstration-therapeutic-equivalence-between-two-inhaled-products-use-treatment-asthma-and-chronic_en.pdf"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.95.08111940"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2019.1575"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.03.035"},{"issue":"1","key":"e_1_3_4_36_2","first-page":"25","article-title":"Comparison of salbutamol efficacy in children\u2013via the metered-dose inhaler (MDI) with Volumatic spacer and via the dry powder inhaler, Easyhaler, with the nebulizer\u2013in mild to moderate asthma exacerbation: A multicenter, randomized study","volume":"29","author":"Direkwatanachai C","year":"2011","unstructured":"Direkwatanachai C, , Teeratakulpisarn J, , Suntornlohanakul S, et al. Comparison of salbutamol efficacy in children\u2013via the metered-dose inhaler (MDI) with Volumatic spacer and via the dry powder inhaler, Easyhaler, with the nebulizer\u2013in mild to moderate asthma exacerbation: A multicenter, randomized study. Asian Pac J Allergy Immunol, 2011; 29(1):25\u201333.","journal-title":"Asian Pac J Allergy Immunol"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200019050-00003"}],"container-title":["Journal of Aerosol Medicine and Pulmonary Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jamp.2024.0045","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2024.0045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jamp.2024.0045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:11:47Z","timestamp":1777644707000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jamp.2024.0045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4,1]]}},"alternative-id":["10.1089\/jamp.2024.0045"],"URL":"https:\/\/doi.org\/10.1089\/jamp.2024.0045","relation":{},"ISSN":["1941-2711","1941-2703"],"issn-type":[{"value":"1941-2711","type":"print"},{"value":"1941-2703","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}